Fig. 2From: Efficacy and safety of rasagiline in Chinese patients with early Parkinson’s disease: a randomized, double-blind, parallel, placebo-controlled, fixed-dose studyAdjusted Changes from baseline in Unified Parkinson’s Disease Rating Scale (UPDRS) total scores at each visit (full analysis set). Data are mean ± standard errorBack to article page